FDA Exploring Limited-Use Approvals For Antibiotics Based On Small Development Programs
This article was originally published in The Pink Sheet Daily
The agency would like to have a “special medical use” category for drugs, such as antibiotics for bacteria resistant to current therapies, that could be approved based on small trials and whose labeling says they should not be prescribed off-label.
You may also be interested in...
FDA “Limited Use” Approval Pathway Gains Traction in Congress
Sens. Michael Bennet, D-Colo., and Orrin Hatch, R-Utah, signal Congressional revival of the Limited Population Antibacterial Development Program, offering antibiotics as the guinea pig for a potentially broader “limited-use” pathway.
Draft Guidances For 2013 Will Grapple With Biosimilars, Track and Trace, Compounding
FDA’s Center for Drug Evaluation and Research plans to publish more than 50 new and revised draft guidances this calendar year.
Antibiotics For Drug-Resistant Infections Hope To Skip Phase III Trials
PhRMA working group lays out proposal to allow approval of antibiotics for infections constituting an unmet medical need based on open-label studies and observational data.